Mansoor Raza Mirza
About Mansoor Raza Mirza
Acrivon Therapeutics appointed Mansoor Raza Mirza, M.D., as Chief Medical Officer effective April 9, 2025; he is listed among the company’s executive officers (age 64) in the 2025 proxy . Dr. Mirza is a world‑renowned gynecologic oncology key opinion leader with decades of clinical development experience, senior authorship on national cancer guidelines, and seven NEJM publications (four as first author); he has led multiple registrational trials resulting in global approvals (including PARP inhibitor Zejula for ovarian cancer and a new frontline endometrial regimen) . At ACRV, he leads clinical development across ACR‑368 (Phase 2b registrational‑intent in endometrial cancer) and ACR‑2316 (Phase 1), aligning his background with the company’s near‑term regulatory objectives and pipeline expansion . Liquidity as of March 31, 2025 was $164.8 million with runway into Q2 2027, informing execution capacity under his tenure .
Past Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| Copenhagen University National Medical Center (Rigshospitalet) | Chief Oncologist | Jul 2009 – Apr 2025 | Led numerous registrational trials and contributed to national guidelines in gynecologic oncology . |
| Nordic Society of Gynecologic Oncology Clinical Trial Unit (NSGO‑CTU) | Medical Director | Apr 2013 – present | Oversees gynecologic oncology clinical trial activities across the Nordic network . |
External Roles
| Organization | Position | Years | Notes |
|---|---|---|---|
| European Society of Gynecological Oncology (ESGO) | Vice‑President | Not disclosed | Senior leadership role in European gynecologic oncology community . |
| Gynecologic Cancer InterGroup (GCIG) | Executive Director | Not disclosed | Coordinates international cooperative clinical research . |
| Karyopharm Therapeutics | Board Member | Not disclosed | Public biopharma board service . |
| Sera Prognostics | Board Member | Not disclosed | Public diagnostics company board service . |
| ESMO | Faculty Member | Not disclosed | Professional society leadership/education . |
| DSKO, ESGO, IGCS, ASCO | Member | Not disclosed | Memberships in key oncology societies . |
Fixed Compensation
| Component | 2025 status for Mirza | Source |
|---|---|---|
| Base salary | Not disclosed in appointment 8‑K or 2025 proxy | |
| Target annual bonus % | Not disclosed | |
| Sign‑on bonus | Not disclosed | |
| Benefits/perqs | Not disclosed |
Reference framework: ACRV’s executive program (for 2024 NEOs, not Mirza) used base salary plus an annual incentive (targets: CEO 55%, EVP 40%, COO 45%) and equity awards, indicating a pay‑at‑risk orientation .
Performance Compensation
| Incentive element | Metric design | Weighting/targets | 2024 precedent (NEOs; not Mirza) | Vesting |
|---|---|---|---|---|
| Annual cash incentive | Corporate and individual objectives | Targets set by Board; examples: CEO 55%, EVP 40%, COO 45% of salary | Board determined 2024 goals achieved and paid early 2025 (amounts per NEO in proxy) | N/A (cash) |
| Stock options | Long‑term value creation; price appreciation | Not disclosed | Grants on 3/1/2024: CEO 225,226; EVP 90,090; COO 90,090; exercise price $5.70; grant date FV disclosed | 25% after 1 year, then 36 equal monthly installments (for 2024 NEO grants) |
| RSUs | Retention and alignment | Not disclosed | Company uses RSUs broadly; no 2025 grants noted in Q2/Q3 10‑Qs | Typical schedules: 25% at 1‑year then 12 quarterly installments; or 1/3 at 1‑year then eight quarterly installments (award‑specific) |
No Mirza‑specific performance metric weightings, targets, or equity grants were disclosed in the 8‑K or 2025 proxy .
Equity Ownership & Alignment
| Item | Detail | Source |
|---|---|---|
| Beneficial ownership (Mirza) | Not disclosed in 2025 proxy tables (as of April 21, 2025); Mirza not enumerated among named holders | |
| Company‑wide RSU activity | Unvested RSUs: 975,550 (12/31/24) → 595,355 (6/30/25) → 406,972 (9/30/25); significant vesting cadence in 2025 | |
| Options outstanding (company) | 4,485,546 (12/31/24) → 6,086,675 (6/30/25) → 5,954,976 (9/30/25) | |
| Shares reserved for future issuance | 2,401,347 (12/31/24) → 3,335,809 (6/30/25) → 3,555,865 (9/30/25) | |
| Inducement plan capacity | Inducement Plan amended April 2025 to add 500,000 shares (often used for new‑hire grants) | |
| Hedging/pledging policy | Insider Trading Policy on file; proxy references policy but does not enumerate hedging/pledging prohibitions in text excerpt |
Implications: Absent Mirza’s Form 3/4 disclosures, his personal ownership and vesting schedule are unknown. Company‑level RSU vesting in 2025 was sizable, implying continued supply from equity settlement across the workforce; watch for Mirza’s inducement/options filings to assess future selling pressure cadence .
Employment Terms
| Term | Mirza (CMO) | Company precedent/context (NEOs; not Mirza) | Source |
|---|---|---|---|
| Employment agreement/offer | Not disclosed in 8‑K or proxy | CEO: salary continuation 12 months + pro‑rata target bonus + up to 12 months COBRA + 12 months continued vesting on time‑based awards for non‑CoC termination; CoC termination: 18 months base + 100% target bonus + 18 months COBRA + full acceleration of time‑based awards | |
| COO/EVP severance | Not applicable to Mirza | EVP (Masson): 9 months salary (plus 3 months AB agreement), pro‑rata target bonus, up to 9 months COBRA, 9 months continued vesting; CoC: 12 months salary + 100% target bonus + 12 months COBRA + full time‑based acceleration. COO (Devroe): 6 months salary; CoC: 6 months salary + full acceleration | |
| Non‑compete / non‑solicit | Not disclosed | Not disclosed in excerpts | — |
| Clawback | Not disclosed | Not disclosed in excerpts | — |
| Change‑of‑control trigger | Not disclosed | CEO/EVP/COO use double‑trigger acceleration for time‑based equity (CoC + qualifying termination) |
Performance & Track Record
- Led clinical programs resulting in multiple global approvals, including Zejula for ovarian cancer and a frontline endometrial regimen combining platinum chemotherapy with anti‑PD‑1; senior author of national endometrial cancer guidelines .
- Will lead ACR‑368 toward regulatory submission/approval and ACR‑2316 Phase 1; company highlighted interim ACR‑368 data (cORR 35% in BM+; cORR 50% in BM+ relapsed subgroup) and early ACR‑2316 activity, supporting value‑creation potential under his leadership .
- Company liquidity: $164.8m at 3/31/25 with runway into Q2 2027, supporting execution of registrational and Phase 1 milestones .
Key Tables
Company RSU activity (vesting cadence)
| Metric | 12/31/2024 | 6/30/2025 | 9/30/2025 |
|---|---|---|---|
| Unvested RSUs (#) | 975,550 | 595,355 | 406,972 |
Company options and share availability
| Metric | 12/31/2024 | 6/30/2025 | 9/30/2025 |
|---|---|---|---|
| Options outstanding (#) | 4,485,546 | 6,086,675 | 5,954,976 |
| Remaining shares reserved for future issuance (#) | 2,401,347 | 3,335,809 | 3,555,865 |
2024 NEO incentive reference (program design; not Mirza)
| Item | CEO | EVP | COO |
|---|---|---|---|
| Target bonus % of salary | 55% | 40% | 45% |
| 3/1/2024 option grant (#) | 225,226 | 90,090 | 90,090 |
| Option vesting | 25% at 1‑yr, then 36 monthly installments | 25% at 1‑yr, then 36 monthly installments | 25% at 1‑yr, then 36 monthly installments |
Gaps and Monitoring Items
- Mirza compensation and equity awards: Appointment 8‑K furnished under Item 7.01 with no offer letter or inducement grant terms; monitor future 8‑Ks and Forms 3/4 for base salary, target bonus, and equity award details/vesting schedule .
- Beneficial ownership/pledging: Mirza was not enumerated in the April 2025 ownership tables; monitor filings for holdings and any pledge disclosures. Insider Trading Policy is referenced, but hedging/pledging specifics not in excerpted text .
Investment Implications
- Positive: Mirza’s proven regulatory track record (multiple approvals, guideline leadership) is well‑matched to ACRV’s near‑term ACR‑368 registrational path and ACR‑2316 progression, potentially de‑risking execution and accelerating timelines .
- Unknowns/risks: Lack of disclosed CMO compensation and severance terms limits visibility into retention economics and alignment; watch for inducement or option grants (Inducement Plan expanded April 2025) and subsequent Form 4s to map vesting‑related supply and selling pressure .
- Supply considerations: Company‑wide equity settlement cadence in 2025 (RSU vesting down from ~976k to ~407k unvested) and growing option overhang suggest ongoing equity supply; Mirza’s own awards could add to periodic supply depending on structure and vesting .
- Execution hinges: Milestones include ACR‑368 registrational/confirmatory design updates and initial ACR‑2316 clinical data in 2H25, which are key catalysts under Mirza’s leadership .